Persistence of Measles, Mumps, and Rubella Antibodies in an MMR‐Vaccinated Cohort: A 20‐Year Follow‐up
Abstract
BACKGROUND: The persistence of antibodies against measles, mumps, and rubella induced by the measles-mumps-rubella (MMR) vaccine and the kinetics of antibody decline after the second MMR vaccine dose were studied in the same cohort for 20 years. METHODS: Measles, mumps, and rubella antibodies were measured by enzyme immunoassay in 20-year follow-up serum samples (n= 183) of twice-vaccinated individuals, and measles antibodies were also measured in oral fluids (n = 177). Antibody decay was determined in a group (n = 58) with subsequent samples collected 1, 8, and 15 years after the second MMR dose. RESULTS: In total, 95%, 74%, and 100% of 183 vaccinees were still seropositive for measles, mumps, and rubella, respectively, and 85% of 177 vaccinees had measurable measles antibodies in their oral fluids. The antibody levels declined significantly after the second dose, but subsequently the rate of decline was slower. CONCLUSIONS: A high rate of seropositivity was found 20 years after the first MMR dose, particularly for rubella and measles. Our results show that MMR vaccine-induced antibodies wane significantly after the second dose. According to epidemiological data, the protection induced by MMR vaccination in Finland seems to persist at least until early adulthood. However, the situation requires constant vigilance.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For vaccines such as measles, mumps, and rubella, published studies have shown neutralizing antibody levels decline by about 5 to 10% per year.
“Published work about many vaccines, such as those against measles, mumps, and rubella, has shown a small decrease each year of 5 to 10% in the neutralizing antibody levels.13,14”
From Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (2021) · cites this paper as [13]
Cites
Expanded Programme on Immunization
Kassianos, G. C. (2001) · doi:10.1002/9780470693841.ch8 · Cited by 397 · see citing works
Rubella Immunity:Defining the Level of Protective Antibody
Skendzel, L. P. (1996) · American Journal of Clinical Pathology · doi:10.1093/ajcp/106.2.170 · Cited by 180 · see citing works
Whittle, H. C., Aaby, P., Samb, B., Jensen, H., Bennett, J. V., & Simondon, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)02364-2 · Cited by 176 · see citing works
Mumps and the UK epidemic 2005
Gupta, R. K., Best, J. M., & MacMahon, E. M. E. (2005) · BMJ · doi:10.1136/bmj.330.7500.1132 · Cited by 166 · see citing works
Briss, P. A., Fehrs, L. J., Parker, R. A., Wright, P. F., Sannella, E. C., Hutcheson, R. H., & Schaffner, W. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.1.77 · Cited by 163 · see citing works
Mumps outbreak in a highly vaccinated population
Hersh, B. S., Fine, P., Kent, W. K., Cochi, S. L., Kahn, L. H., Zell, E. R., Hays, P. L., & Wood, C. L. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80726-7 · Cited by 159 · see citing works
CHRISTENSON, B., & Böttiger, M. (1994) · Vaccine · doi:10.1016/0264-410x(94)90049-3 · Cited by 144 · see citing works
Mumps and rubella eliminated from Finland
Peltola, H. (2000) · JAMA · doi:10.1001/jama.284.20.2643 · Cited by 134 · see citing works
Self-citationPersistence of Measles Antibodies After 2 Doses of Measles Vaccine in a Postelimination Environment
LeBaron, C. W., Beeler, J., Sullivan, B. J., Forghani, B., Bi, D., Beck, C., Audet, S. A., & Gargiullo, P. M. (2007) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.161.3.294 · Cited by 123 · see citing works
Outbreak of mumps in a vaccinated child population: a question of vaccine failure?
Vandermeulen, C., Roelants, M., Vermoere, M., Roseeuw, K., Goubau, P., & Hoppenbrouwers, K. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.02.001 · Cited by 122 · see citing works
Update: Multistate Outbreak of Mumps—United States, January 1-May 2, 2006
(2006) · JAMA · doi:10.1001/jama.295.23.2712 · Cited by 120 · see citing works
Further-Attenuated Measles Vaccine: Characteristics and Use
Krugman, S. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.3.477 · Cited by 109 · see citing works
Davidkin, I., & Valle, M. (1998) · Vaccine · doi:10.1016/s0264-410x(98)00081-4 · Cited by 100 · see citing works
Self-citationNokes, D. J., Enquselassie, F., Nigatu, W., Vyse, A., Cohen, B. J., Brown, D., & Cutts, F. T. (2001) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862001000700003 · Cited by 96 · see citing works
RAPID EFFECT ON ENDEMIC MEASLES, MUMPS, AND RUBELLA OF NATIONWIDE VACCINATION PROGRAMME IN FINLAND
Peltola, H., Kurki, T., Virtanen, M., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92270-1 · Cited by 95 · see citing works
Self-citationWaning antibodies in measles and rubella vaccinees—a longitudinal study
Kremer, J. R., Schneider, F., & Muller, C. P. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.12.015 · Cited by 93 · see citing works
Miller, E. (1995) · Vaccine · doi:10.1016/0264-410x(94)00086-3 · Cited by 91 · see citing works
Johnson, C. E., KUMAR, M. L., Whitwell, J. K., et al. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199608000-00010 · Cited by 89 · see citing works
Persistence of Measles Antibody after Revaccination
Markowitz, L. E., Albrecht, P. G., Orenstein, W. A., et al. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/166.1.205 · Cited by 89 · see citing works
Dai, B., Chen, Z. H., Liu, Q. C., et al. (1991) · PubMed · Cited by 87 · see citing works
Cellular Immunity to Mumps Virus in Young Adults 21 Years after Measles‐Mumps‐Rubella Vaccination
Jokinen, S., Österlund, P., Julkunen, I., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/521029 · Cited by 81 · see citing works
Self-citationDavidkin, I., Peltola, H., Leinikki, P., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00139-0 · Cited by 78 · see citing works
Self-citationPersistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up
Davidkin, I., Valle, M., & Julkunen, I. (1995) · Vaccine · doi:10.1016/0264-410x(95)00064-8 · Cited by 78 · see citing works
Self-citationBoulianne, N., Serres, G. D., Ratnam, S., Ward, B. J., Joly, J. R., & Duval, B. (1995) · Vaccine · doi:10.1016/0264-410x(95)00098-l · Cited by 72 · see citing works
Böttiger, M., & Forsgren, M. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00068-6 · Cited by 70 · see citing works
Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults
CHRISTENSON, B., & Böttiger, M. (1994) · Vaccine · doi:10.1016/0264-410x(94)90009-4 · Cited by 70 · see citing works
Persistence of Vaccine-Induced Antibody to Measles 26–33 Years after Vaccination
Dine, M. S., Hutchins, S. S., Thomas, A., Williams, I., Bellini, W. J., & Redd, S. C. (2004) · The Journal of Infectious Diseases · doi:10.1086/380308 · Cited by 64 · see citing works
Matter, L., Kogelschatz, K., & Germann, D. (1997) · The Journal of Infectious Diseases · doi:10.1086/513967 · Cited by 62 · see citing works
Unique HLA antigen frequencies in the Finnish population
Siren, M., Sareneva, H., Lokki, M., et al. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02695.x · Cited by 54 · see citing works
Abramson, J. S. (2002) · JAMA · doi:10.1001/jama.287.4.505 · Cited by 51 · see citing works
Waning immunity and subclinical measles infections in England
Glass, K. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.02.047 · Cited by 50 · see citing works
Two outbreaks of measles in Germany 2005
Siedler, A., Tischer, A., Mankertz, A., et al. (2006) · Eurosurveillance · doi:10.2807/esm.11.04.00615-en · Cited by 50 · see citing works
MEASLES, MUMPS, AND RUBELLA VACCINE: WHAT COVERAGE TO BLOCK TRANSMISSION?
Nokes, D. J., & Anderson, R. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90920-8 · Cited by 49 · see citing works
Paunio, M., Peltola, H., Valle, M., et al. (1999) · Journal of Epidemiology & Community Health · doi:10.1136/jech.53.3.173 · Cited by 44 · see citing works
Self-citationBroliden, K., Abreu, E. R., Arneborn, M., et al. (1998) · Vaccine · doi:10.1016/s0264-410x(97)88332-6 · Cited by 42 · see citing works
RUBELLA VACCINATION: PERSISTENCE OF ANTIBODIES FOR 10-21 YEARS
O’Shea, S., Woodward, S., Best, J. M., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92512-3 · Cited by 40 · see citing works
Peltola, H., Davidkin, I., Valle, M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(05)65134-3 · Cited by 38 · see citing works
Self-citationLive measles vaccine: a 21 year follow up.
Miller, C. L. (1987) · BMJ · doi:10.1136/bmj.295.6589.22 · Cited by 34 · see citing works
Single point quantification of antibody by ELISA without need of a reference curve
Dopatka, H. D., & Giesendorf, B. A. J. (1992) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860060614 · Cited by 30 · see citing works
Evaluation of Two Enzyme Immunoassays for Detection of Immunoglobulin G Antibodies to Mumps Virus
Backhouse, J. L., Gidding, H. F., McIntyre, P. B., et al. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00199-05 · Cited by 27 · see citing works
Large ongoing rubella outbreak in religious community in the Netherlands since September 2004
Hahné, S. J. M., Ward, M., Abbink, F., et al. (2005) · Weekly releases (1997–2007) · doi:10.2807/esw.10.09.02654-en · Cited by 20 · see citing works
KREMER, J., Bouche, F. B., SCHNEIDER, F., et al. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2005.07.007 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703 · see citing works
Seagle, E. E., Bednarczyk, R. A., Hill, T., Fiebelkorn, A. P., Hickman, C. J., Icenogle, J. P., Belongia, E. A., & McLean, H. Q. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.075 · Cited by 92 · see citing works
- Authors
- Davidkin, I., Jokinen, S., Broman, M., Leinikki, P., & Peltola, H.
- Affiliations
- University of Helsinki (FI)
- Corresponding author
- Davidkin, Irja
- ORCID
- Peltola, Heikki
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04
- Volume
- 197
- Issue
- 7
- Pages
- 950-956
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2148441356
- Cited by
- 329
- References
- 42
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 19 · 2023: 11 · 2022: 19 · 2021: 29 · 2020: 31 · 2019: 25 · 2018: 17 · 2017: 21 · 2016: 17 · 2015: 25 · 2014: 16 · 2013: 18 · 2012: 15
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- MMR vaccine, antibody persistence, antibody waning, seroprevalence, measles antibodies, mumps antibodies, rubella antibodies, second vaccine dose, long-term vaccine protection, Finland
- MeSH terms
- Antibodies, Viral, Child, Female, Finland, Follow-Up Studies, Humans, Immunization, Secondary, Immunoenzyme Techniques, Infant, Male, Measles, Mouth, Mumps, Rubella, Time Factors, Cohort Studies, Measles-Mumps-Rubella Vaccine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
